(Global Executive Moves is a news service brought to you by Kingsley Gate Partners. This should not to be construed as placements made by KGP.)
Private Equity Industry Banner
Mouse Scroll Icon
November 2022

Intervenn Biosciences Announces Erwin Estigarribia as President and Chief Operating Officer

InterVenn Biosciences announced that Erwin Estigarribia has been appointed President and Chief Operating Officer. Prior to his appointment, Erwin was InterVenn’s Chief Operating Officer, where he was instrumental in leading the company’s lab operations and product development efforts. In his new role as President, Erwin will continue to oversee laboratory operations and product development while assuming responsibility for commercial operations and payer engagement. Before joining InterVenn, Estigarribia held executive-level positions at global life sciences companies, including Chiron, Novartis, Geron, Nugen, CardioDX, and Applied Proteomics. 

InterVenn Biosciences identifies, quantifies, and classifies Glycoproteomic and other PTM signals found in human blood and tissue.